You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
On May 15, 2012, FDA granted approval for a generic formulation fixed dose combination of of two antiretroviral medicines, lamivudine and zidovudine tablets, 150 mg/300 mg, (nucleoside reverse transcriptase inhibitors, or NRTIs) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The tablets are manufactured by Lupin Limited, headquartered in Mumbai, India .
FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Combivir Tablets, a product of GlaxoSmithKline.
Approval of this generic formulation means that it may be marketed in the United States.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Products
Food and Drug Administration
.
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
